论文部分内容阅读
为观察可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）和肿瘤坏死因子－α（ＴＮＦ－α）对胃癌的诊断及估计预后的价值，应用酶联免疫双抗夹心法对７８例胃癌患者及对照者血清检测上述两种成分，进行临床观察。结果发现：胃癌患者血清ｓＩＬ－２Ｒ和ＴＮＦ－α水平明显高于胃良性疾病和正常人（均Ｐ＜０．０１）；胃癌Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期（均Ｐ＜０．０１）；手术切除后（根治性或姑息性）ｓＩＬ－２Ｒ和ＴＮＦ－α显著下降（均Ｐ＜０．０１）；手术后复发或转移患者血清中ｓＩＬ－２Ｒ和ＴＮＦ－α含量升高（均Ｐ＜０．０１）；如果患者血清ｓＩＬ－２Ｒ含量高于１０００ｋＵ／Ｌ同时伴有ＴＮＦ－α持续高于１２０μｇ／Ｌ，预兆生存期短。提示监测胃癌患者血清ｓＩＬ－２Ｒ和ＴＮＦ－α水平对临床诊断、病情估计和预后有重要意义
To observe the value of soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in the diagnosis and prognosis of gastric cancer, enzyme-linked immunosorbent assay (ELISA) Control serum test these two components for clinical observation. The results showed that the levels of serum sIL-2R and TNF-α in patients with gastric cancer were significantly higher than those in patients with benign gastric diseases and normal controls (all P <0.01) ). The levels of sIL-2R and TNF-αin the patients with recurrent or metastatic disease were significantly lower after operation (radical or palliative) (all P <0.01) P <0.01). If the level of sIL-2R in serum was higher than 1000 kU / L and TNF-α was still higher than 120 μg / L, the survival time was short. Prompt monitoring of serum sIL-2R and TNF-α levels in patients with gastric cancer clinical diagnosis, prognosis and prognosis of great significance